Optimal therapeutic strategies with CDK4/6 inhibitors based on the real world evidence in patients with HR-positive/HER2-negative advanced and metastatic breast cancer
Not Applicable
Not yet recruiting
- Conditions
- Hormone receptor positive HER2 negative advanced metastatic breast cancer
- Registration Number
- JPRN-UMIN000051975
- Lead Sponsor
- Japan Breast Cancer Research Group(JBCRG)
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Pending
- Sex
- Female
- Target Recruitment
- 400
Inclusion Criteria
Not provided
Exclusion Criteria
non
Study & Design
- Study Type
- Observational
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method
- Secondary Outcome Measures
Name Time Method